JP2024540537A - プログラニュリン発現を調節するための化合物及び方法 - Google Patents

プログラニュリン発現を調節するための化合物及び方法 Download PDF

Info

Publication number
JP2024540537A
JP2024540537A JP2024529579A JP2024529579A JP2024540537A JP 2024540537 A JP2024540537 A JP 2024540537A JP 2024529579 A JP2024529579 A JP 2024529579A JP 2024529579 A JP2024529579 A JP 2024529579A JP 2024540537 A JP2024540537 A JP 2024540537A
Authority
JP
Japan
Prior art keywords
modified
oligomeric compound
modified oligonucleotide
certain embodiments
sugar moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540537A5 (OSRAM
Inventor
ブイ，フィン・ホア
ジャファー・ネジャド，ペイマン
グエン，アンドリュー・トゥアン・ドゥク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of JP2024540537A publication Critical patent/JP2024540537A/ja
Publication of JP2024540537A5 publication Critical patent/JP2024540537A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024529579A 2021-11-18 2022-11-18 プログラニュリン発現を調節するための化合物及び方法 Pending JP2024540537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163281057P 2021-11-18 2021-11-18
US63/281,057 2021-11-18
PCT/US2022/080113 WO2023092057A1 (en) 2021-11-18 2022-11-18 Compounds and methods for modulating progranulin expression

Publications (2)

Publication Number Publication Date
JP2024540537A true JP2024540537A (ja) 2024-10-31
JP2024540537A5 JP2024540537A5 (OSRAM) 2025-11-06

Family

ID=86397858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529579A Pending JP2024540537A (ja) 2021-11-18 2022-11-18 プログラニュリン発現を調節するための化合物及び方法

Country Status (4)

Country Link
US (1) US20250109396A1 (OSRAM)
EP (1) EP4433591A1 (OSRAM)
JP (1) JP2024540537A (OSRAM)
WO (1) WO2023092057A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025032348A1 (en) 2023-08-10 2025-02-13 Harness Therapeutics Limited Functional nucleic acid
WO2025104638A1 (en) * 2023-11-17 2025-05-22 Universita' Degli Studi Di Brescia Antisense oligonucleotides for modulation of progranulin splicing
GB202401412D0 (en) 2024-02-02 2024-03-20 Harness Therapeutics Ltd Functional nucleic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
CN106967799A (zh) * 2017-03-24 2017-07-21 杭州艾迪康医学检验中心有限公司 检测btk基因突变的方法、寡核苷酸及其应用
WO2020191212A1 (en) * 2019-03-20 2020-09-24 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
TW202208628A (zh) * 2020-05-13 2022-03-01 瑞士商赫孚孟拉羅股份公司 靶向顆粒蛋白前體之寡核苷酸促效劑

Also Published As

Publication number Publication date
US20250109396A1 (en) 2025-04-03
EP4433591A1 (en) 2024-09-25
WO2023092057A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
JP7557469B2 (ja) Ａｐｐの発現を低減するための化合物及び方法
JP7557378B2 (ja) Ｓｔｍｎ２発現を増加させるための化合物及び方法
JP2024520205A (ja) Ｕｎｃ１３ａの発現を調節するための化合物
JP7550165B2 (ja) Ｕｂｅ３ａ－ａｔｓを調節するための化合物及び方法
JP2024504377A (ja) Ｄｕｘ４の発現を低減するための化合物及び方法
JP2023536472A (ja) Ａｐｐの発現を低減するための化合物及び方法
EP4192476A2 (en) Compounds and methods for modulating scn2a
US20250109396A1 (en) Compounds and methods for modulating progranulin expression
JP2023511895A (ja) Ｓｍｎ２を調節するための化合物及び方法
JP2026062868A (ja) Ｐｌｐ１を調節するための化合物及び方法
JP2024523363A (ja) Ｉｆｎａｒ１の発現を低減するための化合物及び方法
JP2023543215A (ja) Ａｐｏｅの発現を低減するための化合物及び方法
TW202206596A (zh) 調節ａｔｘｎ１之化合物及方法
JP2026507572A (ja) アルファ－シヌクレイン発現を調節するための化合物および方法
JP2026506010A (ja) Ａｐｐ発現を低減するための化合物及び方法
JP2026506091A (ja) ハンチンチン発現を調節するための対立遺伝子選択的化合物及び方法
WO2024064854A2 (en) Compounds and methods for reducing mecp2 expression
JP2023544162A (ja) Ｃｈｍｐ７を調節するための化合物
JP2023533153A (ja) Ｋｃｎｔ１の発現を低減するための化合物及び方法
JP2025500438A (ja) Ｐｃｄｈ１９発現を低減するための化合物及び方法
HK40129490A (en) Compounds and methods for modulating ube3a-ats
HK40067280A (en) Compounds and methods for modulating ube3a-ats
HK40067280B (en) Compounds and methods for modulating ube3a-ats
JP2024540079A (ja) Ｐｓｄ３発現を低減させるための化合物及び方法
EA043298B1 (ru) Соединения и способы модулирования ube3a-ats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251028